Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATERIAL: Onartuzumab plus erlotinib in first-line MET-positive, EGFR-mutant NSCLC
jRCT2080222031Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of onartuzumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
onartuzumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222031.